European IPF Patient Charter
Sixteen Czech MPs have already signed the “European IPF Patient Charter”. The current number of signatures makes it possible for IPF patients to ask the European Parliament to approve this document. The session is expected to be held on 17 November 2016. If the European IPF Patient Charter is approved, IPF patients will become more empowered to demand equal access to diagnostic methods, treatment including lung transplantation, information on IPF, and palliative care for all IPF patients across the EU.
As regards IPF treatment, there are large inequalities among EU member states: for example, antifibrotic therapy is not reimbursed from the public health insurance in many countries (Poland, Slovakia, Hungary). But even in countries where antifibrotic therapy is paid from public resources, there are various conditions for reimbursement, such as limitations related to values of pulmonary function tests, or stopping the reimbursement if there is a certain decrease in pulmonary function (the so-called “stopping rules”). In some EU countries, reimbursement is solely linked to the IPF diagnosis and drugs can be prescribed by pulmonary specialists in general; in other countries, drugs can be only prescribed by specialists in centres recognised by health insurance companies.
You can find more information about the European IPF Patient Charter (and possibly add your signature) at www.ipfcharter.org.
Download
- European IPF Patient Charter (
PDF file, 93 kB)
29. 9. 2016 plicnifibroza.cz
   |
  |